Health Care·Health Care Services·$10.0B
DaVita Inc. is a leading provider of kidney care services in the healthcare sector, focusing on dialysis treatments for patients with chronic kidney disease....
Earnings Per Share (EPS)
EPS is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
Revenue growth is essential for assessing the company's ability to expand and sustain its operations.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
1Q
EPS Beat Rate
75%
Avg EPS Surprise
+3.33%
Avg Stock Reaction
+0.90%
In Q4 2025, DaVita reported an EPS of $3.40, exceeding expectations by 5.07%. This positive surprise contributed to a slight increase in the stock price the following day.
Management Promises & Guidance
Analysts expect DaVita to report solid earnings this quarter, with a consensus EPS of $2.33 and revenue of $3.4 billion. The company's recent performance has created a cautiously optimistic outlook.
Bull Case
If DaVita beats EPS estimates, it could signal strong operational performance and patient growth, potentially driving the stock higher.
Bear Case
Conversely, if the company misses expectations, it may raise concerns about its ability to maintain profitability and manage costs, leading to a negative reaction in the stock.
Earnings Per Share (EPS)
$2.33EPS is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$3.4BRevenue growth is essential for assessing the company's ability to expand and sustain its operations.
The print will turn on these two things.
Q1
Will DaVita's EPS exceed the consensus estimate of $2.33?
A beat on EPS would reinforce investor confidence in the company's profitability and operational efficiency.
Q2
What are the revenue figures and growth trends in the kidney care segment?
Understanding revenue performance is crucial for assessing the company's market position and future growth potential.
Why consensus could be wrong
The consensus may underestimate DaVita's ability to manage costs effectively, given recent operational improvements and patient growth initiatives.
Supporting Evidence
The company has consistently beaten EPS estimates in 75% of the last quarters.
Recent operational efficiencies may not be fully reflected in analyst models.
The healthcare sector's resilience during economic fluctuations suggests DaVita's revenue may hold steady.
Key Risk
If DaVita reports revenue significantly above $3.4 billion, it could challenge the current bearish outlook.
Pre-commit to what would confirm each case.
This quarter's performance will be closely scrutinized as investors look for signs of growth amidst rising healthcare costs.
Bull Confirmed If
An EPS of $2.40 or higher would confirm strong operational performance and growth.
Bear Confirmed If
An EPS below $2.20 could indicate challenges in maintaining profitability.
Implied Move
±4.2%
The options market is pricing in a potential move of 4.2% around the earnings report, indicating some uncertainty among investors.
Cross-company pattern from 30 similar setups.
Prior-quarter beat setup in Health Care
n=30Fade rate: 8 of 20 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 8 of 20 faded and 12 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.9%, with a raw directional average of +2.4% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If DaVita beats expectations, history suggests the stock could rise by around 1.46%, confirming positive market sentiment.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss on earnings could lead to a decline of approximately 0.78%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026